You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0743 Secukinumab Improves Multiple Parameters of Disease Activity in Subjects with Active Ankylosing Spondylitis Through 52 Weeks of Subcutaneous Therapy: Data From the Phase 3 Measure 2 Study

Article info

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Spondyloarthritis - treatment
AB0743 Secukinumab Improves Multiple Parameters of Disease Activity in Subjects with Active Ankylosing Spondylitis Through 52 Weeks of Subcutaneous Therapy: Data From the Phase 3 Measure 2 Study

Authors

Citation

Braun J, Sieper J, Aelion J, et al
AB0743 Secukinumab Improves Multiple Parameters of Disease Activity in Subjects with Active Ankylosing Spondylitis Through 52 Weeks of Subcutaneous Therapy: Data From the Phase 3 Measure 2 Study
Annals of the Rheumatic Diseases 2015;74:1147.

Publication history

  • First published June 9, 2015.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions